Kapitel 48: Mammakarzinom


American Society of Human Genetics (ASHG) (2000) 50th meeting of the October 4–7


Bässler KH (1992) Histopathologie der Mamma. IAP Deutsche Abteilung, Bonn


Bonadonna G, Zametti M, Valagussa P (1995b) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542–547


Bonneterre J, Buzdar A, Robertson J et al. (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9): 2247–2258


Chan S, Friedricks K, Noel K et al. (1997) A randomized phase III study of Taxotere® versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results. Proc ASCO, Abstr 540

Chan, S., G. Romieu et al. (2005). Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Journal of Clinical Oncology 23(No 16S (June 1 Supplement)): 581

Chao Y, Liu JM, Hung HC et al. (1998) Biweekly continuous infusion chemotherapy (M-FLEEP) plus megestrol acetate for advanced cancer. Proc ASCO, Abstr 1109


Chen J, Silver DP, Walpita D et al. (1998c) Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2: 317‒328


Cummings SR, Norton L, Eckert S et al. for the MORE Investigators (1998) Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. 2–year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc ASCO 17: 3


De Wolf CJM (1992) Europäische Leitlinien für die Qualitätssicherung bei Mammographie-Reihenuntersuchung, Europa gegen den Krebs. KEG-Verlag, Klagenfurt


Fisher B, Dignam J, Bryant J et al. (1996a) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88: 1529–1542

Fisher B, Dignam J, Wieand S et al. (1996b) Duration of Tamoxifen (TAM) therapy for primary breast cancer: 5 versus 10 years (NSABP B-14). Proc ASCO, Abstr 15


Gianni AM, Siena S, Bregni M et al. (1997a) Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15: 2312–2321

Gianni L, Capri G, Mezzelani A et al. (1997b) HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. Proc ASCO 16, Abstr 491

GIVIO investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 271: 1587–1592


Hall PA, Lane DP (1994) $p53$ in tumour pathology: can we trust immunohistochemistry? — Revisited! J Pathol 172: 1–4


Harbeck N, Look MP, Ulm K, Duffy MJ on behalf of the Pooled Analysis Study of the EORTC Receptor and Biomarker Group (RBG) (2001) UPA and PAI-1 ready for routine testing in primary breast cancer: pooled analysis (n=8,377) provides level-1 evidence for clinical relevance. Proc ASCO, Abstr 1646


Hortobagyi GN, Porter L, Theriault RL et al. (1997) Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy, by monthly 90 mg pamidronate (ArediaR) infusions Proc ASCO, Abstr 530

Hortobagyi GN, Buzdar AU, Champlin R et al. (1998) Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC) — A randomized trial. Proc ASCO 17, Abstr 471


Jänicke F, Prechtl A, Thomssen C et al. (2001) for the German Chemo N0 Study Group. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 93: 913‒920


Jordan VC, Glusman JE, Eckert S et al. (1998) Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women. Proc ASCO, Abstr 466


Klijn JGM, Beex L, Mauriac L et al. (1997a) Addition of LHRH-Agonist to tamoxifen (TAM) improves survival in metastatic breast cancer: Detailed Analysis of EORTC study 10881. ICC, Abstr 840


Kovach JS, Hartmann A, Blaszyk H et al. (1996) Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093‒1096


Lipton A, Theriault R, Leff R et al. (1997) Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions Proc ASCO, Abstr 531


Lynch ED, Ostermeyer EA, Lee MK et al. (1997) Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61: 1254‒1260


Möbus VJ, Lueck HJ, Thomssen C et al. (2006) Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4+ LN). Mature results of an AGO-trial. SABCS 2006, #43


National Cancer Institute (ed) Statement from the National Cancer Institute on the National Cancer Advisory Board recommendations on mammography. Available on NCI’s web site, Cancer Net


O'Shaughnessy JA, Blum J, Moiseyenko V et al. (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9): 1247–54


Pegram MD, Pienkowski T, Northfelt DW et al. (2004) Results of two open label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2–positive advanced breast cancer. JNCI 96: 759–769


Peters WP (1995a) High dose chemotherapy as adjuvant therapy for breast cancer: were do we stand? 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, March 1–4, Abstract 19


Reigner BG, Glynne-Jones R, Cassidy J et al. (1998) Hepatic dysfunction due to liver metastasis does not affect the bioactivation of Xeloda. Proc ASCO, Abstr 863

Remmelo W, Stegner HE (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue], Pathologe 8(3): 138–40


Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen (1998) Dtsch Ärzteblatt 95: A1396


Rodenhuis S, Richel DJ, van der Wall E et al. (1998) A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Proc ASCO 17, Abstr 470


Schubert EL, Lee MK, Mefford HC et al. (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60: 1031‒1040

Schubert EL, Mefford HC, Dann JL et al. (1997) BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genet Test 1: 41‒46


Scull R, Anderson SF, Chao DM et al. (1997a) BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 94: 5605‒5610

Scull R, Chen J, Plug A et al. (1997b) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265‒275

Scull R, Chen J, Ochs RL et al. (1997c) Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90: 425‒435


Serova OM, Mazoyer S, Puget N et al. (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer susceptibility genes? Am J Hum Genet 60: 486‒495


Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B et al. (1996) Truncations at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Can Res 56: 3216–3219


Solomayer EF, Diel IJ, Gollan C et al. (1997) Tumor cell detection in breast cancer patients before and after neo-adjuvant chemotherapy. Proc ASCO 16: 192a


Taguchi T, Adachi I, Enomoto K et al. (1994) Docetaxel (RP56976) in advanced or recurrent breast cancer early and late phase II clinical studies in Japan. Proc ASCO, Abstr 152


Theriault R, Buzdar AU, Hortobagyi GN et al. (1998) Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy. Proc ASCO 17, Abstr 381


Ursin G, Henderson BE, Haile RW et al. (1997) Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57: 3678


Wiltschke C, Krainer M, Budinsky A et al. (1995) Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer. Brit J Cancer 71: 1292‒1296
Yarden RI, Brody LC (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96: 4983‒4988
Zhang, Somasundaram K, Peng Y et al. (1998) BRCA1 physically interacts with p53 and stimulates its transcriptional activity. Oncogene 16: 1713‒1721